title: Plateletpheresis concentrates produced with the COMTEC cell separator: the French experience.
abstract: The latest generation of cell separators such as Trima (Gambro), Amicus (Baxter) and AS-TEC 204 (Fresenius), allow the collection of leucocyte-reduced platelet concentrates without secondary filtration. Fresenius has recently developed the COMTEC cell separator whose performance has been evaluated by several teams in France. This new cell separator is an improved version of the Fresenius AS-TEC 204 cell separator, designed to allow more efficient platelet collections. This study reports on the experience of six French teams (from Bordeaux, Clermont-Ferrand, Creteil, Dijon, Lille and Nancy) who obtained 696 leucocyte-reduced plateletpheresis concentrates in the course of collection using the new Fresenius COMTEC cell separator. All healthy volunteer donors fulfilled French selection criteria for platelet apheresis. Donors were eligible if they had suitable venous accesses, if their bodyweight was *50 kg and if their pre-apheresis platelet count was >150 x 10(9) l(-1). Between 4606 and 5229 ml of blood were processed. The mean volume of the platelet concentrates was between 439 and 493 ml (mean 460 +/- 63 ml). The platelet yield was of the order of 5.18 +/- 1.02 x 10(11) with only one platelet concentrate below the norm of 2 x 10(11) platelets (0.91 x 10(11)). No plausible explanation for this was found. The residual leucocyte levels conform to current norms. The platelet concentrates contained less than 1 x 10(6) leucocytes per concentrate (mean 0.233 +/- 0.150 x 10(6) leucocytes) in more than 97% of the components produced with >95% statistical confidence. The efficacy of the cell separator (52.44 +/- 7.35%) is comparable to that of other separators. The Fresenius COMTEC cell separator makes it possible to obtain leucocyte-reduced platelet concentrates which comply with current standards both in terms of platelet content and residual leucocyte level.
authors.affiliation: EFS Bourgogne Franche Comtè, Dijon Site, BP, France. christian.coffe@efs.sante.fr
authors.forename: C
authors.initials: C
authors.lastname: Coffe
authors.forename: M
authors.initials: M
authors.lastname: Benguella
authors.forename: M
authors.initials: M
authors.lastname: Domy
authors.forename: D
authors.initials: D
authors.lastname: Cottier
authors.forename: F
authors.initials: F
authors.lastname: Guignier
authors.forename: J P
authors.initials: JP
authors.lastname: N'gondara
authors.forename: A
authors.initials: A
authors.lastname: Carrère
authors.forename: M
authors.initials: M
authors.lastname: Masse
authors.forename: C
authors.initials: C
authors.lastname: Naegelen
authors.forename: B
authors.initials: B
authors.lastname: Biggio
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: P
authors.initials: P
authors.lastname: Hervè
authors.forename: R
authors.initials: R
authors.lastname: Bouzgarrou
authors.forename: J P
authors.initials: JP
authors.lastname: Maurel
authors.forename: G
authors.initials: G
authors.lastname: Vezon
authors.forename: M
authors.initials: M
authors.lastname: Vidal
authors.forename: F
authors.initials: F
authors.lastname: Quainon
authors.forename: A
authors.initials: A
authors.lastname: Benamara
authors.forename: B
authors.initials: B
authors.lastname: Lamy
authors.forename: J L
authors.initials: JL
authors.lastname: Beaumont
authors.forename: P
authors.initials: P
authors.lastname: Bierling
authors.forename: G
authors.initials: G
authors.lastname: Gondrexon
authors.forename: F
authors.initials: F
authors.lastname: Schooneman
authors.forename: C
authors.initials: C
authors.lastname: Janot
authors.forename: F
authors.initials: F
authors.lastname: Villard
authors.forename: J J
authors.initials: JJ
authors.lastname: Huart
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects; D001782:Blood Donors; D001810:Blood Volume; D001835:Body Weight; D019343:Citric Acid / Q000009:adverse effects; D004867:Equipment Design; D005260:Female; D005602:France; D005947:Glucose / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008212:Lymphocyte Depletion / Q000295:instrumentation; D008297:Male; D010976:Platelet Count; D010983:Plateletpheresis / Q000295:instrumentation*; D012449:Safety
chemical_list: D000925:Anticoagulants; C002113:acid citrate dextrose; D019343:Citric Acid; D005947:Glucose